Shares of Denali Therapeutics (DNLI) rose marginally yesterday after the company reported third-quarter results on Wednesday.Denali incurred a third-quarter 2024 loss of 63 cents per share, wider than the Zacks Consensus Estimate of a loss of 60 cents. The company reported a loss of 72 cents in the year-ago quarter.The bottom line improved year over year despite a rise in operating expenses, mainly due to an increase in the number of shares outstanding.In the absence of a marketed product, the company only ...